Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart J C, Laudet V, Staels B
U.325 INSERM, Département d'Athérosclérose, Institut Pasteur, and the Faculté de Pharmacie, Université de Lille II, Lille, France.
J Biol Chem. 1998 Oct 2;273(40):25713-20. doi: 10.1074/jbc.273.40.25713.
Fibrates are widely used hypolipidemic drugs which activate the nuclear peroxisome proliferator-activated receptor (PPAR) alpha and thereby alter the transcription of genes controlling lipoprotein metabolism. Fibrates influence plasma high density lipoprotein and its major protein, apolipoprotein (apo) A-I, in an opposite manner in man (increase) versus rodents (decrease). In the present study we studied the molecular mechanisms of this species-specific regulation of apoA-I expression by fibrates. In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels. The absence of induction of rat apoA-I gene expression by fibrates is due to 3 nucleotide differences between the rat and the human apoA-I promoter A site, rendering a positive PPAR-response element in the human apoA-I promoter nonfunctional in rats. In contrast, rat, but not human, apoA-I transcription is repressed by the nuclear receptor Rev-erbalpha, which binds to a negative response element adjacent to the TATA box of the rat apoA-I promoter. In rats fibrates increase liver Rev-erbalpha mRNA levels >10-fold. In conclusion, the opposite regulation of rat and human apoA-I gene expression by fibrates is linked to differences in cis-elements in their respective promoters leading to repression by Rev-erbalpha of rat apoA-I and activation by PPARalpha of human apoA-I. Finally, Rev-erbalpha is identified as a novel fibrate target gene, suggesting a role for this nuclear receptor in lipid and lipoprotein metabolism.
贝特类药物是广泛使用的降血脂药物,可激活核过氧化物酶体增殖物激活受体(PPAR)α,从而改变控制脂蛋白代谢的基因转录。贝特类药物对人体血浆高密度脂蛋白及其主要蛋白质载脂蛋白(apo)A-I的影响与啮齿动物相反(人体中升高,啮齿动物中降低)。在本研究中,我们研究了贝特类药物对apoA-I表达的这种物种特异性调节的分子机制。在原代大鼠和人肝细胞中,非诺贝特酸分别降低和升高了apoA-I mRNA水平。贝特类药物不能诱导大鼠apoA-I基因表达是由于大鼠和人apoA-I启动子A位点之间存在3个核苷酸差异,使得人apoA-I启动子中的阳性PPAR反应元件在大鼠中无功能。相反,大鼠而非人的apoA-I转录受到核受体Rev-erbalpha的抑制,Rev-erbalpha与大鼠apoA-I启动子TATA框相邻的负反应元件结合。在大鼠中,贝特类药物使肝脏Rev-erbalpha mRNA水平增加10倍以上。总之,贝特类药物对大鼠和人apoA-I基因表达的相反调节与它们各自启动子中顺式元件的差异有关,导致大鼠apoA-I被Rev-erbalpha抑制,人apoA-I被PPARα激活。最后,Rev-erbalpha被鉴定为一种新的贝特类药物靶基因,表明该核受体在脂质和脂蛋白代谢中起作用。